Trial Profile
A Phase I, Open-Label Study to Investigate the Tolerability and Safety of IBI310 Alone or in Combination With Sintilimab in the Treatment of Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Sintilimab (Primary)
- Indications Acral lentiginous melanoma; Malignant melanoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Innovent Biologics
- 21 Sep 2021 Updated results (n=44; As of April 14, 2021) assessing safety and efficacy of IBI310 alone or in combination with sintilimab in patients with advanced melanoma, presented at the 46th European Society for Medical Oncology Congress.
- 29 Aug 2021 According to an Innovent Biologics media release, data will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2021.
- 02 Jun 2020 According to an Innovent Biologics media release, preliminary results (as of 12th Nov 2019, n=10 in Phase 1a study and n=17 subjects in Phase 1b study) were announced in the form of online publication at the 56th American Society of Clinical Oncology (ASCO) Annual Meeting. (Online publication, Abstract # 302489).